Drugs Manufacturer from Hyderabad on overdrive

Optimus Pharma gets DCGI nod for conducting Phase III Clinical Trials for Molnupiravir on patients with mild and moderate COVID-19 infection

Hyderabad (Telangana) [India], May 19: Optimus Pharma on Tuesday received DCGI nod for conducting Phase III Clinical Trials for orally administered Molnupiravir capsules on patients with Mild and Moderate Covid-19 symptoms. With a severe shortage of antiviral drugs in the market against the SARS-CoV-2 infection, it is imperative that more drugs with potent antiviral activity against SARS-CoV-2 be introduced.

Optimus pharma said having internally developed the active pharmaceutical ingredient (API) and the formulations for the product, it had filed for clinical trials with the DCGI. The regulator gave a nod for conducting the trial on mild and moderate patients on May 18 2021.

As per the clinical trial, protocols approved, a total of 2500 subjects in both mild and moderate COVID-19 will be randomised in the study in a 1:1 ratio to Molnupiravir with standard supportive care or standalone standard supportive care. The treatment duration is a maximum of 05 days and the total study duration will be a maximum for 29 days from randomisation, the release said.

“Optimus is all geared to immediately begin clinical trials on Molnupiravir on COVID-19 patients in India. The clinical trial will let us know the efficacy of this molecule on COVID-19 patients,” Chairman & Managing Director – Dr. D Srinivas Reddy said.

In the previous press release, the company stated that Molnupiravir demonstrated highly promising results in reducing viral load to 0.0% in merely 5 days of treatment duration. Based on completed phase 2 part clinical studies, the proposed dosage is 800mg twice daily which significantly reduces viral culture in infected patients not progressing into ARDS.

Optimus Pharma is one of the largest manufacturers of the highly successful SARS-CoV-2 antiviral drug without compromising on quality as is the case with Favipiravir (sold under the brand – FAVICOVID).  The company aims to do the same with Molnupiravir to cater to the rising demand for Anti-Viral drugs against SARS-CoV-2 in the Indian market.

With the cooperation of the government and our stakeholders, and a special thanks to the Subject Expert Committee of the CDSCO for their valuable contribution and their recommendations to the project, we hope to deliver the product in India by leveraging our solid distribution strength across the country.

Health

On This Doctors Day: Gynaecologist’s Advice on PCOS, Menopause & Screening in Pregnancy

New Delhi (India), July 1: Today, on Doctor’s Day, we gather to pay homage to a remarkable group of medical professionals – gynecologists, the champions of women’s health. These compassionate healers work tirelessly, providing comprehensive care and guidance to women in every stage of life. From adolescence to motherhood, from menopause to beyond, gynecologists are the […]

Read More
Health

Digital Marketer Sociomark Bags Digital Mandate for Ayu Health

Mumbai (Maharashtra) [India], June 15: Sociomark, a Mumbai-based digital marketing agency, proudly announces its recent triumph in securing the digital mandate for Ayu Health, the largest & most trusted healthcare brand in India. Following an extensive agency selection process that involved multiple pitches, Sociomark emerged as the ideal partner to bolster Ayu Health’s digital footprint. […]

Read More
Health

Non-Surgical, Next Generation Cryoablation Technology- A Boon for Cancer Patients

Mumbai (Maharashtra) [India], June 9: Cancer patients in India can now heave a sigh of relief, thanks to the availability of cryoablation technology in the country. Cryoablation is a minimally invasive image-guided (ultrasound or CT scan) treatment that uses extreme cold to freeze and accurately destroy diseased tissue within the tumour zone.  This technology is the brainchild of […]

Read More